Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Marco Matucci-Cerinic,1 Christopher P Denton,2 Daniel E Furst,3 Maureen D Mayes,4 Vivien M Hsu,5 Patrick Carpentier,6 Fredrick M Wigley,7 Carol M Black,2 Barri J Fessler,8 Peter A Merkel,9 Janet E Pope,10 Nadera J Sweiss,11 Mittie K Doyle,12–14 Bernhard Hellmich,15,16 Thomas A Medsger Jr,17 Adele Morganti,18 Fabrice Kramer,18 Joseph H Korn,9 James R Seibold13

ABSTRACT

Objectives Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, for ‘Randomized, double-blind, Placebo-controlled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis’) was conducted to more fully evaluate the effects of bosentan treatment on DUs associated with SSc.

Methods This double-blind, placebo-controlled trial conducted at 41 centres in Europe and North America randomised 188 patients with SSc with at least 1 active DU (‘cardinal ulcer’) to bosentan 62.5 mg twice daily for 24 weeks (n=98) or matching placebo (n=90; total 24 weeks). The two primary end points were the number of new DUs and the time to healing of the cardinal ulcer. Secondary end points included pain, disability and safety.

Results Over 24 weeks, bosentan treatment was associated with a 30% reduction in the number of new DUs compared with placebo (mean±standard error: 1.9±0.2 vs 2.7±0.3 new ulcers; p=0.04). This effect was greater in patients who entered the trial with more DUs. There was no difference between treatments in healing rate of the cardinal ulcer or secondary end points of pain and disability. Peripheral oedema and elevated aminotransferases were associated with bosentan treatment.

Conclusions Bosentan treatment reduced the occurrence of new DUs in patients with SSc but had no effect on DU healing. Bosentan was well tolerated and may be a useful adjunct in the management of patients with SSc with recurrent DUs.

INTRODUCTION

Intimal hyperplasia, endothelial dysfunction and occlusive vascopathy are ubiquitous features of systemic sclerosis (SSc). These vascular lesions are the underlying basis of important clinical syndromes in SSc, including scleroderma renal crisis, pulmonary arterial hypertension (PAH) and Raynaud’s phenomenon.1 Patients with SSc are at high risk for the development of ischaemic digital ulcers (DUs), which occur in 55% to 60% of patients with SSc2–5 and are an important source of morbidity. Among a cohort of 2080 patients with SSc identified between 1972 and 1995 and prospectively followed-up for a mean of 10 years, 58% of patients had a history of DUs.6 Of all patients with SSc, 52% (666 patients) had persistent or recurrent DUs for 6 months; of these, 30% (197 patients) had severe DUs (complicated by gangrene, or requiring digital sympathectomy or amputation). In one series, the incidence of finger amputation as a consequence of DUs was 1.2% per patient-year.6

The pathogenesis of DUs is thought to include many of the hallmark processes of critical tissue ischaemia, such as impaired afferent vasomotion, microvascular disruption, reduced venous drainage, increased local platelet activation and increased leucocyte adherence.1 As a result, no single pharmacological treatment is entirely effective. Nifedipine and intravenous iloprost reduced the frequency and severity of SSc-related Raynaud’s phenomenon attacks,7 and iloprost was shown to improve DU healing in another trial that included patients with active DUs.8 Few studies have been specifically designed to examine efficacy in the prevention or treatment of DUs. Nifedipine and intravenous iloprost resulted in the reduction from baseline in the mean number of DUs in a small study.7 Similarly, a trial in patients with severe PAH associated with SSc9 indicated there may be a beneficial effect of epoprostenol on the number of DUs. In a recent small placebo-controlled study, atorvastatin reduced the number of new DUs in association with improvement in markers of endothelial function.10

Indirect evidence implicates endothelin (ET) as a potential mediator of the vascular dysfunction in SSc. Plasma ET concentrations are increased in patients with SSc, and there is evidence for increased ET1 receptor expression in lung, skin and blood vessels in this disease.11 Other actions of ET relevant to SSc include proinflammatory and proliferative effects as well as mediation of vasoconstriction.12 ET receptor antagonists including bosentan are now commonly used for the treatment of PAH in SSc.13–15

A previous double-blind, randomised, placebo-controlled trial investigated the role of bosentan in the reduction of new DUs in 122 patients with SSc...
and a history of DUs within the previous year. After 16 weeks of treatment, patients receiving bosentan had a 48% reduction in the mean number of new DUs compared with placebo (1.4 vs 2.7 new ulcers; p=0.0083), but there were no differences between treatments in end points assessing DU healing in the 63% of patients with active DUs at baseline.

The present study (RAPIDS-2, for ‘Randomized, double-blind, Placebo-controlled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis’) was designed to further investigate the effects of bosentan as a treatment for DUs secondary to SSc over a 24-week treatment period in a larger population of patients, all of whom had active DUs at study entry. The primary objectives were to evaluate the effect of bosentan on the reduction of new DUs and healing of DUs in patients with SSc. Secondary objectives were to evaluate the effect of bosentan on pain and disability, as well as its tolerability and safety in these patients.

PATIENTS AND METHODS

Study design

This double-blind, randomised, parallel-group, placebo-controlled study consisted of a ≤2-week screening period, a 24-week treatment period and an 8-week post-treatment follow-up period. The study was approved by local ethics committees and conducted in accordance with the amended Declaration of Helsinki. All patients gave written informed consent.

Settings and participants

The study was conducted from October 2003 to May 2005 at 41 centres in Europe and North America. Recruited patients were ≥18 years old, with SSc as defined by the preliminary classification criteria of the American College of Rheumatology (ACR) and at least one active DU (onset between 1 week and 3 months prior to randomisation) that was selected by the investigator and termed the ‘cardinal ulcer’ (painful area, ≥2 mm in diameter with visible depth and loss of dermis, amenable to healing and in a location judged compatible with a vascular aetiology, specified by protocol as volar surface of the digit distal to the proximal interphalangeal digital crease).

Patients were excluded if they had received intravenous prostanooids within the previous 3 months, had used phosphodiesterase inhibitors other than for intermittent treatment of male erectile dysfunction, or had received inhaled or oral prostanooids or injected botulinum toxin in an affected finger within 1 month. Patients were also excluded if they received systemic antibiotics to treat infected DUs within 2 weeks prior to randomisation. Also excluded were patients with body weight <40 kg, severe PAH (WHO class III/IV), moderate to severe hepatic impairment or serum aminotransferase levels >3 times the upper limit of the normal range (ULN). Contraceptive measures and monthly pregnancy testing were required during and for 3 months after the end of study treatment.

Randomisation and interventions

After screening, patients were randomised to bosentan or placebo (1:1 ratio) by sequential allocation of randomisation numbers distributed to each centre in blocks of four. Patients received bosentan 62.5 mg twice daily for 4 weeks and then 125 mg twice daily for the remainder of the treatment period or matching placebo. The dose could remain at or be decreased to the starting dose due to intolerance, with possible subsequent increase to the target dose. Concomitant use of systemic antibiotics, analgesics and topical treatments for wound care were allowed, and randomised treatment was administered in addition to the usual, stable (over the previous month) treatment for Raynaud’s phenomenon. Patients who required parenteral, oral or inhaled prostanooid treatment during the study were first discontinued from study treatment. Use of glibenclamide, fluconazole, calcineurin inhibitors or ciclosporin A was not allowed due to potential drug interactions.

Outcomes

The two primary end points were (1) the mean number of new DUs per patient assessed by the investigator up to week 24 and (2) the time to healing of the cardinal ulcer up to week 24 in patients with cardinal ulcer healing maintained for 12 or more weeks. Healing was defined as complete epithelialisation, regardless of residual pain. Maintenance of cardinal ulcer healing required no recurrence at or contiguous to the original location at week 24 (if healing occurred before or at week 12) or during 12 weeks of observation with permissible extension of the treatment period (if healing occurred after week 12). To verify that the effect of treatment would not vary substantially across relevant baseline subgroups, the number of new DUs up to week 24 was additionally analysed in subgroups based on predefined baseline factors associated with disease severity.

Secondary and exploratory end points included: (1) reduction of new DUs and overall DU number (proportions of patients with no new DUs and with each number of new DUs up to week 24, time to onset of each number of new DUs up to week 24 and change from baseline to week 24) in the overall patient population and in subgroups defined by randomisation month (October–February or autumn–winter and March–September or spring–summer) and (2) number of new DUs, time to each successive new DU and proportions of patients with healing of all DUs by the end of week 24 (and (3) pain and disability parameters (changes from baseline to week 24: in pain of the cardinal ulcer and overall hand pain assessed on visual analogue scales; hand disability index (an averaged score from the three Health Assessment Questionnaire (HAQ) domains of dressing/grooming, grip and hygiene); and HAQ disability index).

Post hoc analyses included: (1) the number of new DUs up to week 12 in the overall patient population and in subgroups defined by randomisation month (October–February or autumn–winter and March–September or spring–summer) and (2) number of new DUs, time to each successive new DU and total number of DUs through week 24 in subgroups defined by the number of DUs at baseline (<4 and ≥4).

Patients were evaluated at randomisation/baseline and every 4 weeks during treatment (or premature withdrawal, week 24 and, if applicable, 12 weeks after healing of the cardinal ulcer), with DUs assessed at each study visit. Safety was continually monitored.

Statistical methods

Efficacy analyses were performed on all treated patients using SAS software (SAS Institute, Cary, North Carolina, USA). Means±SEs are presented for numerical variables and Kaplan–Meier estimates for time-to-event variables. Treatment effects for the primary end points were evaluated using the Pitman permutation (new DUs) and log-rank test with asymptotic approximation (time to healing of the cardinal ulcer). Missing data on new DUs were imputed using extrapolation, with the incidence rate of new DUs at the last assessment corrected for the missing time period. The worst of either the calculated number or observed values at week 24 was used for patients who prematurely discontinued study treatment. Patients with no
valid assessment post baseline (three patients on bosentan, one on placebo) were excluded from the main analysis. Treatment effects for new DUs in predefined subgroups were presented as point estimates and 95% two-sided CIs.

For exploratory purposes, statistical tests of treatment difference were provided for planned secondary/exploratory and unplanned post hoc efficacy analyses and included the Pitman permutation (for changes from baseline), the Fisher exact test (for proportions) and the log-rank test (for times to event), each performed without correction for multiple testing. Placebo-corrected changes from baseline, RR and HRs from Cox modelling were each reported with 95% CIs where appropriate. Safety and baseline data were summarised descriptively, with no statistical testing planned or given.

RESULTS
The two treatment groups were well matched with respect to demographic features, baseline disease characteristics and concomitant treatment for DUs at baseline (table 1). All 188 randomised patients received study treatment, with mean exposures of 22.7±0.9 and 24.5±0.9 weeks in the bosentan and placebo groups, respectively. The treatment period was completed by 75/98 (76.5%) and 73/90 (81.1%) patients, respectively (figure 1), with 9.2% and 7.8%, respectively, discontinued due to an adverse event.

Primary end points
New DUs
After 24 weeks of bosentan treatment there was a 30% reduction in the occurrence of new DUs compared with placebo in the study population (1.9 (95% CI 1.4 to 2.3) vs 2.7 (2.0 to 3.4) new DUs, p=0.0351, figure 2). Fewer new DUs were observed with bosentan than placebo in all subgroups except among current smokers (table 2, subgroup analyses). This included subgroups of limited and diffuse SSc, with no difference between the two subgroups in the treatment effect (overlapping 95% CIs).

Healing of the cardinal ulcer
No difference between bosentan and placebo treatments was observed in the time to healing of the cardinal ulcer (HR 0.91 (95% CI 0.61 to 1.35), p=0.63, figure 3). At week 24, more than 50% of patients in both groups had healing of the cardinal ulcer maintained for at least 12 weeks.

Secondary and exploratory end points
New DUs
The proportion of patients with no new DUs up to week 24 was similar with bosentan and placebo (observed in 32/95 (33.7%) and 26/89 (29.2%) patients, respectively, RR 1.15 (95% CI 0.75 to 1.77); p=0.53). The proportion of patients with one or more new DU was 66.3% (63/95) on bosentan compared with 70.8% (63/89) on placebo; the difference in observed proportions between treatments was greater in patients with multiple new DUs (18.9% vs 29.2% with ≥4, 10.5% vs 29.8% with ≥5, etc; figure 4). The maximum number of new DUs per patient was 10 on bosentan and 16 on placebo. Time-to-event analyses up to week 24 indicated an increasing reduction in risk with bosentan compared with placebo for the appearance of each successive new DU, with a HR of 0.45 (95% CI 0.21 to 0.95, p=0.03) for the fifth new DU. However, the mean total number of DUs (baseline and new) per patient decreased to a similar extent in the bosentan and placebo groups (−1.7 (95% CI −2.3 to −1.0) and −1.5 (−2.3 to −0.7) DUs, respectively; p=0.76).

DU healing
No treatment effects were observed in the times to healing up to week 24 for all baseline DUs (HR 0.94 (95% CI 0.65 to 1.37), p=0.74) or of all new DUs (HR 1.40 (0.78 to 2.51), p=0.26). Healing of all DUs (baseline and new combined) at week 24 was observed in 35/95 (36.8%) and 35/89 (39.3%) of patients on bosentan and placebo, respectively (RR 0.94 (95% CI 0.65 to 1.35), p=0.76).

Table 1  Demographics and baseline characteristics of the study population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo (n=90)</th>
<th>Bosentan (n=98)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men/women, % of patients</td>
<td>20/80</td>
<td>22/78</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>50.7 (12.0)</td>
<td>48.4 (12.9)</td>
</tr>
<tr>
<td>Weight in kg, mean (SD)</td>
<td>66.5 (15.8)</td>
<td>64.7 (13.6)</td>
</tr>
<tr>
<td>Caucasian/black/other, % of patients</td>
<td>83/6/11</td>
<td>87/7/6</td>
</tr>
<tr>
<td>Smoking status, % of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never/previous/current</td>
<td>56/23/22</td>
<td>64/23/13</td>
</tr>
<tr>
<td>SSc characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited/diffuse, % of patients</td>
<td>58/42</td>
<td>60/40</td>
</tr>
<tr>
<td>Time from diagnosis of scleroderma to randomisation in years, mean (SD)</td>
<td>8.7 (7.7)</td>
<td>8.7 (8.4)</td>
</tr>
<tr>
<td>DU characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number at baseline, mean (SD)</td>
<td>3.6 (3.3)</td>
<td>3.7 (4.4)</td>
</tr>
<tr>
<td>Time from first occurrence of DUs to randomisation in years, mean (SD)</td>
<td>6.4 (7.1)</td>
<td>7.4 (8.7)</td>
</tr>
<tr>
<td>Selected concomitant medication at baseline, % of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>56</td>
<td>50</td>
</tr>
<tr>
<td>Anti-inflammatory and antirheumatic products</td>
<td>37</td>
<td>40</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>Peripheral vasodilators§</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Angiotensin II receptor blockers</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Phosphodiesterase inhibitor (sildenafil)</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

*Other races included Asian, Hispanic, Indian, Native American and mixed.
†Smoking status was available for 88 and 94 patients in the placebo and bosentan groups, respectively, and the time from first occurrence of DUs to randomisation for 89 and 98 patients, respectively.
‡Limited=skin thickening only distal to the elbows and knees. Diffuse=skin thickening proximal to the elbows or knees or affecting the trunk.
§As defined by the WHO Drug Dictionary and included pentoxifylline, buflomedil, ginkgo tree leaves extract and ginkgo biloba.
ACE, angiotensin-converting enzyme; DU, digital ulcer; SSc, systemic sclerosis.
Extended report

**Table 2** Number of new DUs up to week 24 in predefined and post hoc subgroups of patients

<table>
<thead>
<tr>
<th>Planned subgroup analyses</th>
<th>n Placebo</th>
<th>n Bosentan</th>
<th>Treatment effect</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SSc classification:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse</td>
<td>37</td>
<td>37</td>
<td>2.1 (1.4 to 2.9)</td>
<td>-0.6 (1.8 to 0.6)</td>
</tr>
<tr>
<td>Limited</td>
<td>52</td>
<td>59</td>
<td>1.7 (1.1 to 2.2)</td>
<td>-1.0 (2.1 to 0.0)</td>
</tr>
<tr>
<td><strong>Time from diagnosis of DU to randomisation:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 years</td>
<td>49</td>
<td>54</td>
<td>1.7 (1.2 to 2.2)</td>
<td>-1.0 (2.2 to 0.1)</td>
</tr>
<tr>
<td>&gt;5 years</td>
<td>39</td>
<td>41</td>
<td>2.1 (1.2 to 2.9)</td>
<td>-0.7 (1.8 to 0.5)</td>
</tr>
<tr>
<td><strong>Systemic antibiotics for DU:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>11</td>
<td>16</td>
<td>2.6 (1.1 to 4.0)</td>
<td>-2.5 (5.7 to 0.8)</td>
</tr>
<tr>
<td>No</td>
<td>77</td>
<td>76</td>
<td>1.7 (1.2 to 2.2)</td>
<td>-0.7 (1.5 to 0.1)</td>
</tr>
<tr>
<td><strong>Local treatment for DU:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>24</td>
<td>33</td>
<td>2.1 (1.3 to 2.9)</td>
<td>-0.7 (2.0 to 0.6)</td>
</tr>
<tr>
<td>No</td>
<td>64</td>
<td>61</td>
<td>1.8 (1.2 to 2.3)</td>
<td>-0.9 (2.0 to 0.1)</td>
</tr>
<tr>
<td><strong>Dose adjustment of treatment for Raynaud’s phenomenon:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>19</td>
<td>22</td>
<td>1.8 (0.9 to 2.6)</td>
<td>-1.8 (3.6 to 0.1)</td>
</tr>
<tr>
<td>No</td>
<td>69</td>
<td>72</td>
<td>1.9 (1.4 to 2.4)</td>
<td>-0.6 (1.5 to 0.3)</td>
</tr>
<tr>
<td><strong>Smoking habit at baseline:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>49</td>
<td>58</td>
<td>2.2 (1.6 to 2.9)</td>
<td>-0.8 (1.9 to 0.3)</td>
</tr>
<tr>
<td>Previous</td>
<td>20</td>
<td>22</td>
<td>1.3 (0.7 to 2.0)</td>
<td>-2.0 (4.0 to -0.1)</td>
</tr>
<tr>
<td>Current</td>
<td>19</td>
<td>12</td>
<td>1.5 (0.4 to 2.6)</td>
<td>0.2 (1.0 to 1.3)</td>
</tr>
<tr>
<td><strong>Post hoc subgroup analyses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number DUs at baseline:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;4</td>
<td>60</td>
<td>59</td>
<td>1.6 (1.1 to 2.0)</td>
<td>-0.3 (1.1 to 0.4)</td>
</tr>
<tr>
<td>≥4</td>
<td>29</td>
<td>36</td>
<td>2.4 (1.5 to 3.2)</td>
<td>-2.1 (3.8 to -0.4)</td>
</tr>
<tr>
<td><strong>Randomisation month:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 2003 to February 2004</td>
<td>37</td>
<td>29</td>
<td>0.7 (0.4 to 1.0)</td>
<td>-0.6 (1.3 to 0.1)</td>
</tr>
<tr>
<td>March 2004 to September 2004</td>
<td>52</td>
<td>64</td>
<td>0.8 (0.5 to 1.2)</td>
<td>-0.4 (1.0 to 0.2)</td>
</tr>
</tbody>
</table>

Data are mean (95% CIs).

*Exploratory p value determined using the Pitman permutation.
†Analysis confined to the first 12 weeks of treatment to avoid overlap of seasons.
DU, digital ulcer; SSc, systemic sclerosis.

**Pain and disability**

Patient-rated measures of overall hand pain and pain of the cardinal ulcer, as assessed by visual analogue scales, showed no differential treatment effect in pain at week 24 (mean treatment effects of -1.7 (95% CI -11.4 to 7.9), p=0.73 and -1.6 (-11.5 to 8.3), p=0.75, respectively). The changes from baseline in the HAQ disability index and hand disability index at week 24 were also similar in both treatment groups (-0.04 (95% CI -0.15 to 0.08), p=0.51 and -0.04 (-0.20 to 0.12), p=0.62, respectively).

**Post hoc analyses of new DUs**

In unplanned post hoc analyses in subgroups defined by the number of DUs at baseline, the mean treatment effect with bosentan was -2.1 (95% CI -3.8 to -0.4) new DUs (p=0.02) in patients with at least four DUs at baseline and -0.3 (-1.1 to...
serious event (pneumonia) reported for more than one patient on bosentan. One patient on placebo died from acute respiratory distress syndrome during the post-treatment follow-up. The proportions of patients experiencing at least one adverse event were similar in both treatment groups (table 4). Adverse events occurring in more patients on bosentan than placebo included peripheral oedema (18.8% vs 4.4%) and events denoting elevated aminotransferases (12.5% vs 2.2%). These adverse events resulted in premature discontinuation of bosentan treatment in 2.1% and 5.2% of patients, respectively (vs none on placebo). Overall, adverse events led to the discontinuation of study treatment in 15.6% of patients on bosentan and 12.2% on placebo. Laboratory tests identified increased aminotransferases to >3×ULN in 10/95 (10.5%) patients on bosentan (which included one patient with an elevation to >8×ULN) and 1/88 (1.1%) patients on placebo. In all cases on bosentan, elevated aminotransferases resolved during continued treatment, after a decrease in dose, or following temporary or permanent treatment discontinuation.

**DISCUSSION**

In this randomised, placebo-controlled trial, bosentan treatment was associated with a 30% reduction in the number of new DUs over the 24-week treatment period but did not result in a treatment effect on healing of the cardinal ulcer. The reduction of new DUs was more pronounced among patients with multiple DUs; large numbers of new DUs were less likely to occur, and the appearance of each successive new DU was delayed in patients on bosentan compared with those on placebo. Based on post hoc analyses, the reduction of new DUs appeared to be greater in patients with at least four DUs at baseline.

**Safety and tolerability**

Serious adverse events occurred in 9.4% and 16.7% of patients on bosentan and placebo, respectively (table 4), with only one new DUs (p=0.39) in patients with less than four DUs at baseline (table 2). In both subgroups, the estimated proportion of patients without each subsequent new DU was larger in the bosentan than placebo group except the first new DU (table 3), and the difference between treatment groups was larger among patients with at least four new DUs than in those with fewer than four new DUs. No difference between treatments was observed in the mean total number of DUs (baseline plus new) per patient among patients with at least four DUs at baseline (−3.4 (95% CI −4.8 to −1.9) on bosentan and −3.6 (−5.4 to −1.7) DUs on placebo) and those with fewer than four DUs at baseline (−0.6 (−1.0 to −0.2) and −0.5 (−1.1 to 0.1) DUs, respectively).

An analysis of subgroups based on randomisation month (October–February, March–September) confined to the first 12 weeks of treatment (to avoid overlapping time periods) found no effect of season on the treatment effect (table 2).

**Figure 3** Kaplan–Meier estimates of time to complete healing of the cardinal ulcer.

**Figure 4** Proportions of patients with new digital ulcers (DUs) by number of new DUs up to week 24. Patients in the placebo group had up to 16 new DUs.

**DISCUSSION**

In this randomised, placebo-controlled trial, bosentan treatment was associated with a 30% reduction in the number of new DUs over the 24-week treatment period but did not result in a treatment effect on healing of the cardinal ulcer. The reduction of new DUs was more pronounced among patients with multiple DUs; large numbers of new DUs were less likely to occur, and the appearance of each successive new DU was delayed in patients on bosentan compared with those on placebo. Based on post hoc analyses, the reduction of new DUs appeared to be greater in patients with at least four DUs at baseline.

The mean total number of DUs per patient at week 24 was similar in the two treatment groups, and no treatment effects were observed in the other measures of healing or patient-rated measures of pain and disability used. This is the second randomised placebo-controlled trial to show a reduction in the number of new DUs in susceptible patients with SSc treated with bosentan. Consistent with the first trial, the observed treatment effect was greater in patients with multiple DUs, while there was no effect on healing parameters.16
Dermatitis 2 (2.2) 5 (5.2)
Urinary tract infection 3 (3.3) 5 (5.2)
Skin ulcer/disease progression 7 (7.8) 5 (5.2)
Nausea 11 (12.2) 5 (5.2)
Pain in extremity 4 (4.4) 6 (6.3)
Diarrhoea 8 (8.9) 6 (6.3)
Upper respiratory tract infection 7 (7.8) 8 (8.3)
Infected skin ulcer 6 (6.7) 9 (9.4)
Headache 11 (12.2) 9 (9.4)
Arthralgia 6 (6.7) 10 (10.4)
Elevated aminotransferases* 2 (2.2) 12 (12.5)
Peripheral oedema 4 (4.4) 18 (18.8)

All patients with ≥1 adverse event 76 (84.4) 83 (86.5)
Peripheral oedema 4 (4.4) 18 (18.8)
Elevated aminotransferases* 2 (2.2) 12 (12.5)
Arthralgia 6 (6.7) 10 (10.4)
Headache 11 (12.2) 9 (9.4)
Infected skin ulcer 6 (6.7) 9 (9.4)
Upper respiratory tract infection 7 (7.8) 8 (8.3)
Diarrhoea 8 (8.9) 6 (6.3)
Pain in extremity 4 (4.4) 6 (6.3)
Nausea 11 (12.2) 5 (5.2)
Skin ulcer/disease progression 7 (7.8) 5 (5.2)
Urinary tract infection 3 (3.3) 5 (5.2)
Dermatitis 2 (2.2) 5 (5.2)
Other† 70 (77.8) 78 (81.3)
All patients with ≥1 serious adverse event 15 (16.7) 9 (9.4)

*Reported by investigators as alanine aminotransferase increased, aspartate aminotransferase increased and liver function test abnormal.
†Includes all adverse events with an incidence on bosentan <5%.

The reduction of new DUs without effect on healing in bosentan-treated patients did not translate into a smaller ulcer burden, as was seen in the previous study. In this study, similar reductions in the overall number of DUs (present at baseline and/or new) occurred in both groups. The difference between studies could not be explained by a seasonal effect on the appearance of new DUs due to the different enrolment periods (October–September vs October–February in the first study). Raynaud’s phenomenon is thought to be more severe and new DUs more frequent during the autumn and winter, but the numbers of new DUs in autumn/winter and spring/summer randomisation subgroups were nearly identical. The but the numbers of new DUs in autumn/winter and spring/summer periods (October–September vs October–February in the first study) could not be explained by a seasonal effect in this study were similar to previous reports. The increased incidence of peripheral oedema with bosentan was not previously reported in patients with DUs but has been seen in other patient populations.

This was a large and complex controlled trial, but there are limitations to the data interpretation. The definition of an active DU used in this trial may not match criteria used in other centres. The clinical utility of this promising approach to treatment may be challenged. In a patient encountered with a single DU, initiation of bosentan would not be expected to facilitate healing, and at least 66% of all bosentan-treated subjects would develop at least one additional DU over 6 months of follow-up. However, in those patients presenting with multiple DUs (at least four), the effect of bosentan treatment on the reduction of new DUs offers greater potential benefit. Major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that reduced occurrence of DUs would ultimately reduce the risk of same in an appropriate population.

In conclusion, two randomised trials have shown that bosentan treatment reduces the occurrence of new DUs compared with placebo in patients with SSc but has no effect on DU healing. Bosentan was well tolerated and may be a useful adjunct in the management of patients with SSc and recurrent DUs.

**Acknowledgements** We thank all contributing investigators and their staff. Austria: M Aringer, P Fritsch; Canada: M Baron, P Lee, E Rich; France: C Frances, E Hachulla, Germany: H-H Peter, T Krieg, M Meurer; Italy: C Ferri, F Salsano, R Scorzà; Spain: J Roman; Switzerland: S Oertle; UK: S Bowman, B Griffiths; USA: S Collier, M Csuka, A Goldberg, B Kahaleh, D Khanna, H Kenney, J Molitor, T Osborn, N Rothfield, E Smith.

**Funding** This study was funded by Actelion Pharmaceuticals, Allschwil, Switzerland.

**Competing interests** MMC has received fees for speaking and research grant from Actelion Pharmaceuticals and Pfizer, and has received fees for speaking from Glaxo-Smith-Kline Beecham. CPD has received research grant funding to support clinical research fellows, honoraria for lecturing and been a consultant to Actelion Pharmaceuticals, Encysive Pharmaceuticals, Genuity, Aspreva Pharmaceuticals, Pfizer, Biovittoria and DiGNA. DEF has received grants for research from Actelion and Gilead, has consulted regarding trial design for the same companies and has received funds for being a Continuing Medical Education speaker from Actelion. MDM has received payments from Novartis to participate in a Data Safety Monitoring Board for a clinical trial of a drug not currently on the market; and to conduct a clinical trial of a new agent for scleroderma. MDM has received payments from MedQuest to conduct a clinical trial of topical nitrogen preparation to treat Raynaud’s phenomenon. VMH has received honoraria and travel expenses from Actelion Pharmaceuticals for serving on an advisory board.
PC has received fees from Actelion Pharmaceuticals as a speaker and moderator at the ‘Journée Française de la Sclérodermie Systémique’ in 2006 and 2007 and for participation in the Scientific Board on Systemic Sclerosis (2003–2008). FMW has been compensated for presenting in lecture format materials and data from studies related to the use of bosentan; FMW was an investigator in the RAPIDS-2 trial supported by Actelion. BJF has received funds for consulting from Actelion, Encysive and Gilead, for research from Actelion, and for speaking from Encysive and Gilead; PAM has received research funding from the following companies, each of which are involved in research related to the topic of this article: Actelion, Encysive, Genentech, Genzyme and Novartis. JEP has been a consultant and speaker for Actelion. Research in this study and other studies was funded by Actelion. MKD has received honoraria and travel expenses from Actelion Pharmaceuticals for serving on an advisory board and was an investigator for the RAPIDS-2 trial supported by Actelion. BH has received speaker honoraria from Actelion Pharmaceuticals, the manufacturer of bosentan. TAM has been paid honoraria by Actelion for giving lectures unrelated to Actelion products. FK is a full-time employee of and holds stock options in Actelion Pharmaceuticals. AM is a full-time employee of Actelion Pharmaceuticals Italia Srl and holds stock options in Actelion Pharmaceuticals. JHK received research funding from the following companies, each of which are involved in research related to the topic of this article: Actelion and Genzyme. JRS has funded research and a consultancy agreement with Actelion Pharmaceuticals, the sponsor of this study. JS, in the past, received honoraria for lectures supported by Actelion. He also has funded research and consultancy relationships with Pfizer, Encysive, United Therapeutics, Centocor, FibroGen, Bristol-Myers Squibb, Lilly, Genzyme and Gilead, all of which have commercial interests in treating scleroderma and its vascular complications. No conflicts of interest are reported by CMB and NJS.

Contributors The Steering Committee (consisting of six of the authors) along with the study’s sponsor (Actelion Pharmaceuticals) designed the trial and supervised its conduct. The investigators and sponsor collected trial data. The authors had full access to the data, prepared the manuscript without compensation by the sponsor and had full responsibility for the final decision to submit the paper. Medical writing assistance with the development of the manuscript was provided by Dr Karen Manchester (funded by Actelion Pharmaceuticals).

Ethics approval This study was conducted with the approval of the Local Ethics Committees at each of 41 study sites in Austria, Canada, France, Germany, Italy, Spain, Switzerland, UK and USA.

Provenance and peer review Not commissioned; externally peer reviewed.

Author affiliations 1Department of Biomedicine, Division of Rheumatology, University of Florence, Florence, Italy
2Centre for Rheumatology, Royal Free and University College Medical School, London, UK
3Division of Rheumatology, UCLA School of Medicine, University of California, Los Angeles, California, USA
4Division of Rheumatology, University of Texas Health Science Center at Houston, Houston, Texas, USA
5UMDNJ Scleroderma Program, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
6Service de Médecine Interne, CHU Albert Michalov, Grenoble, France
7Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
8Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA
9Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
10Division of Rheumatology, Saint Joseph Health Care, London, Ontario, Canada
11Division of Rheumatology, University of Chicago, Chicago, Illinois, USA
12Section of Clinical Immunology, Allergy, and Rheumatology, Tulane University School of Medicine, New Orleans, Louisiana, USA
13Centocor RD, Malvern, Pennsylvania, USA
14Section of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
15Department of Rheumatology, University of Lübeck, Bad Bramstedt, Germany
16Department of Medicine, Plochingen General Hospital, Plochingen, Germany
17Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
18Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
19University of Connecticut Health Center, Farmington, Connecticut, USA

REFERENCES